Abstract
The COVID-19 caused by a novel coronavirus, named Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has taken a great toll of life affecting lakhs of people around the globe. It was detected initially in Wuhan, China and has spread rapidly to more than 208 countries to date. A range of molecular and immunoassay-based techniques ranging from central laboratory testing to point-of-care tests is urgently needed for the diagnosis and management of COVID-19 patients. Intensive research is going on for the rapid and highly sensitive detection of COVID 19 using varied approach. Hence, this review will focus on the structure of SARS-CoV-2 and recent progress of different detection tool for the detection of COVID-19. This review will also stimulate academics and researcher to update their current technology. Additionally, we also state about the future revolving around the detection of the novel coronavirus. Lately, the way ahead for better management are also put forward.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
1 Introduction
The year 2019 ended with a fatal outbreak of a novel coronavirus, Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), preliminarily identified as a causative agent of a series of unusual pneumonia cases in Wuhan City, Hubei Province, China. The International Committee on Taxonomy of Viruses (ICTV) permanently named the pathogen SARS-CoV-2 and the disease it caused coronavirus disease 2019 (COVID-19) and declared the crisis a pandemic (Enserink 2020). As per the World Health Organisation (WHO), latest situation report (Sep 14, 2020) at the time of this writing, more than 28.9 million confirmed cases with more than millions of deaths have been reported in 208 countries (Organisation 2020). The first reported case of COVID-19 was in Wuhan, Hubei province with symptoms such as fever, cold, shortness in breath very similar to the common cold in few cases and within a week had a reported cluster cases of acute pneumonia (Nishiura et al. 2020). The Computerized Tomography (CT) scan of the patients revealed slight opacity and difference from the healthy scan of the lungs (Ai et al. 2020).
2.2 CRISPR-Cas based testing
Another aspect to be explored for detecting COVID-19 is making use of CRISPR-Cas gene editing tool which can create wonders in the field of detection (Chekani-Azar et al. 2020). Making use of CRISPR-Cas has been reported for use in medicine and diagnostics over the years. Success in making use of the CRISPR-Cas has enabled to ascertain new systems for targeting and manipulating nucleic acids including those from Cas9, Cas12, Cascade and Cas13 orthologues (Pickar-Oliver and Gersbach 2019; Li et al. 2019). Possibilities of develo** a diagnostic tool for detection of TB is already known using CRISP-Cas technology which lay the foundation for making its use in COVID-19 detection as well (Ai et al. 2019). Very recently, developed SARS-CoV-2 DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) for detection of COVID-19 using CRISPR-Cas12. This developed lateral flow strip could decrease the detection time required by the ongoing RT-PCR testing and aid in better disease management in this crucial time (Broughton et al. 2020). Exploiting the potential of CRISPR-Cas technology fluorescence and colorimetric based detection of COVID-19 was made possible. The technology is named as specific high-sensitivity enzymatic reporter unlocking (SHERLOCK) by making use of recombinase-mediated polymerase pre-amplification of DNA or RNA for detection. The reported technology takes less than an hour to provide results making it one of the potent applicants in the field of diagnosis of COVID-19 (Kellner et al. 2019). An improved version of SHERLOCK was put forward which overcome major challenges of SHERLOCK and is named as STOP (SHERLOCK testing in one pot). The mentioned assay is capable of solely performing extraction, amplification and CRISPR-mediated detection of the viral RNA in a go on a single temperature. Two version are presented as STOP covid version 1 and 2 respectively. STOP covid version 1 is compatible with lateral-flow and fluorescence readouts whereas STOP covid version 2 makes use of magnetic beads concentrated SARS-CoV-2 RNA for detection (Joung et al. 2020). CREST is another pioneering discovery in the field of diagnosis for detection of COVID-19. The CREST stands for (Cas13-based, Rugged, Equitable, Scalable Testing) and has overcome major drawbacks associated with the current diagnostic system of COVID-19. The Cas13 can be used in point of care setting and it would be low cost when compared to traditional lateral flow assay as it doesn’t require antibody conjugates for the detection (Rauch et al. 2020). Another effective use of CRISPR Cas 12 was seen by integrating into a lateral flow system named as iSCAN having potential to be used as effective management system for point of care detection(Ali et al. 2020). AIOD CRISPR assay, made use of a pair of crRNAs to initiate the detection using CRISPR-Cas12a for improved sensitivity. The assay have potential in detecting nucleic acids (DNA and RNA) of SARS-CoV-2 and HIV (Ding and Yin 2020). Integration of lateral flow system along with nucleic acid as a substrate for quick and point of care results can prove to be fruitful amid this pandemic as shown in Fig. 3a. Another perspective to be explored is pairing CRISPR-Cas with electrochemical based sensing as it can help in achieving even lower limit of detection. Can Dincer et.al, reported (CRISPR)/Cas13a-powered microfluidic based electrochemical sensor for detection of cancer reaching a limit of 10 pM on site (Bruch et al. 2019). Such a system should be made available at this crucial time in detection of COVID-19. Development of CRISPR-Cas based on-chip electrical detection of nucleic acid could be the future of detection in COVID-19 screening as it can detect even in femto Molar levels (Hajian et al. 2019).
2.3 Protein based testing
Along with the on-going nucleic acid-based testing for detection of COVID-19 protein-based detection can also act as an excellent supplement alongside for better mass screening for early measures in a point of care setting. Although nucleic acid, CRISPR-Cas and aptamer-based testing are currently been employed for detection protein-based avenues needs to be explored. Antigen and antibody are the among the major protein-based entities which are already used for detection of several diseases over a long time. Protein-based detection system mostly includes ELISA, chromogenic based or fluorescence-based detection using dye, lateral flow-based detection. Not much was developed until recently since the viral load has reported fluctuating with weeks after detection providing results which are not possibly reproducible when test was made using saliva sample from infected patients. Viral load was highest at the start and subsequently declined at the end (To et al. 2020). Although it can be speculated that antibody-based test can provide more time since antibody can be detected even after a long time in the patient.
2.3.1 Antigen based testing
An antigen test has ability to reveals if a person is presently infected with a pathogen such as the SARS-CoV-2 virus. Antigen tests mostly detect proteins or glycans, such as the spike proteins found on the surface of the SARS-CoV-2 virus. Sona nanotech is one of the pioneers in the filed leading the way of COVID-19 testing by develo** antigen-based test kit for detection. The gold nanorod particles used are CTAB (cetyltrimethylammonium) free hence limiting the toxic risks associated with the use of other gold nanorod technologies in medical applications. It was reported recently that the test attained a positive response to a recombinant whole spike protein control reagent specific to SARS-CoV2 and neither had false positives (Nanotech 2020). Another milestone is reached by E25Bio’s rapid diagnostic which provide results in 15 min by detecting the presence of the virus in the patient sample (Misra 2020). Iceni Diagnostics run by Prof Rob Field, has developed a diagnostic technique that make use of an artificial glycan receptor to detect the novel virus (Iceni Diagnostics Ltd 2020). OraSure envisions is another established name being working on develo** antigen based testing kit (OraSure Technologies 2020). Roche has reported of develo** test having sensitivity of 96.52% and a specificity of 99.68%, based on 426 samples from two independent study centers the test helps in identifying both symptomatic and asymptomatic people with in 15 min (Roche Ltd 2020a). Lately special consideration is being given to point of care antigen testing in order to detect infected person at the earliest and decreasing the chances of mass transfer of the virus (Dinnes et al. 2020). However, it was reported that antigen based detection alone cannot be effective in detection of SARS-CoV-2 (Mak et al. 2020).
2.3.2 Antibody based detection
Major class of immunoglobins includes of IgG, IgM, IgA, IgE and IgD which can contribute in detection of diseases. IgG been the first line of defense initiated as part of the immune response when infected by a pathogen and creates immunological memory to further fight the infection is mostly targeted in detection of COVID-19. Also reported is that IgM appears in the blood of the patient when infected by SARS after 3 to 6 days and IgG can be detected 8 days after the infection occurred (Racine and Winslow 2009; Wan et al. 2003).
IgG and IgA ELISAs in conjunction with the EURO Lab workstation (Euroimmun, Lübeck, Germany). EUROIMMUN enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgA and IgG antibodies in serum and plasma samples using recombinant S1 domain of the SARS-CoV-2 spike protein as antigen is reported demonstrates excellent sensitivity for detection of IgA and IgG antibodies from samples collected ≥3 days and ≥ 4 days, respectively, after COVID-19 diagnosis by PCR (Beavis et al. 2020). Other ELISA based IgG and IgA showed specificity of 91.9% and 73.0% 12 and 11 days after symptom onset (Jääskeläinen et al. 2020). Many industries as well have developed ELISA based detection kit for COVID-19 like Epitope diagnostic, Inc. and Eagle bioscience although tests are yet to be approved by FDA for use. Eagle bioscience test kits are now available for use in the US for detection (Epitope Diagnostics 2020; Bioscience 2020). Making use of protein for detection is known and adopted for development over decades but recently making use of neutralizing antibody had been adopted to fight against the novel coronavirus. The antibody targets the spike protein of the virus which is made up of two subunits the S1 and S2. The S1 subunit is necessary for entry into the host cell while S2 subunit helps in fusion of the cellular and viral membrane. SARS-CoV-2 binds the receptor human angiotensin-converting enzyme 2 (ACE2) (Wang et al. 2020a).Considering the fact that neutralizing antibodies have great potential to fight the diseases making its use in disease diagnosis could be the near future. On evaluation of IgM/IgG based detection kit the highest specificity was reported for the Wantai SARS-CoV-2 Total Antibody ELISA followed by 93% for the Euroimmun IgA ELISA and 96% for the Euroimmun IgG ELISA with sensitivities of 90%, 90%, and 65%, respectively (Lassaunière et al. 2020).
Development of lateral flow strip for detection makes use of antigen-antibody reaction. Here the reaction occurs on the nitrocellulose membrane. Once the sample is added into the strip the antigen interacts with the already loaded capture antibody for detection through capillary action. The gold nanoparticle-conjugated antibody is present near the sample port to interact with the sample for the formation of the visible color change after formation of the immunocomplex. Making use of lateral flow assay for diseases detection which makes use of antigen-antibody for detection can be a better alternative for COVID-19 diseases management. Lateral flow assay(LFA) is well established in terms of diseases detection and been used for more than a decade as shown in Fig. 3b (Bahadir and Sezgintürk 2016).
Building on this concept various lateral flow strip has been developed lately (Li et al. 2011; Martinez et al. 2008). Table 1 represents the available list of commercial SARS-CoV-2 in-vitro diagnostic assays.
4 Conclusion and future prospect
The development and research have ramped up at a greater speed than ever in the field of diseases diagnosis due to COVID-19 outbreak leading to an increase in the mortality rate each day in an unpredictable manner. Still countries are struggling to speed up testing due to the laborious and expensive RT-PCR lab technique, which often require centralized services. Few RT-PCR based innovative diagnostic methods are in the developmental stage which detect viral materials in different ways such as gene editing tool CRISPR. But, need of the hour in this pandemic is the development and establishing innovative diagnostic tool which would be easy to use, accurate, sensitive and point of care. Although point of care serological tests (lateral flow immunoassay based) is readily available in the market for COVID-19 detection but still the quality of commercial kits needs to be re-evaluated due to occurrence of false positive results. The lateral flow-based immunoassay has advantages over RT-PCR in develo** nations were the facilities for RT-PCR set up is scare. However, the lateral flow immunoassay does not give an explicit picture of the severity of the disease but can help as an aid the detection alongside with RT-PCR technique.
With the available technology, the diagnosing of the disease could be a menace shortly. Although the process of technology development is hurtling up day by day integrating them for a better output is essential. In our view, following developments can make an advanced COVID -19 detection tools (Fig. 5): 1) Making isothermal amplification-based LFA could be one of the alternatives in hand to overcome the problem with current lateral flow assay of giving false negative results. 2) Paper-based device with real-rime simultaneous detection of multiple DNA targets can be developed for highly sensitive and specific detection, 3) Nanotechnology intervention in the pipeline of disease detection can be potentially fruitful, 4) Development needs to be made in making use of microfluidic devices for development of new prototype for early point of care detection of the novel virus. Even screening of close biomarkers for development of accurate and precise diagnostics kit is necessary, 5) Efforts need to be made for technology forward approach by integrating it to smartphone mobile devices which are omnipresent in nature, 6) Making CRISPR-Chip based electrical detection can help us to detect the analyte even at lower concentration, 7) Development of novel face mask which in turn is integrated with an sensor can help in detecting even lower limit of virus 8) Making use of electrochemical based device as it can detect even narrow antigenic load. There is also possibility to explore the development of point-of-care tests with multiplex assays and breathe analyzer. With integration with technology it will be easy not only to identify the people suffering and also take measure as early as possible for better diseases management.
Research in the field of COVID-19 is evolving quickly and new data are generated each day. Some referenced manuscripts are preprints and have not been peer-reviewed.
Data availability
Not applicable.
References
Abbott: Abbott launches Covid-19 antibody test (2020). https://www.abbott.com/corpnewsroom/product-andinnovation/abbott-launches-covid-19-antibody-test.html. Accessed 15 May 2020.
D.-G. Ahn, I.-J. Jeon, J.D. Kim, M.-S. Song, S.-R. Han, S.-W. Lee, H. Jung, J.-W. Oh, RNA aptamer-based sensitive detection of SARS coronavirus nucleocapsid protein. Analyst 134, 1896–1901 (2009)
J.-W. Ai, X. Zhou, T. Xu, M. Yang, Y. Chen, G.-Q. He, N. Pan, Y. Cai, Y. Li, X. Wang, CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis. Emerg. Microbes Infect. 8, 1361–1369 (2019)
T. Ai, Z. Yang, H. Hou, C. Zhan, C. Chen, W. Lv, Q. Tao, Z. Sun, L. **a, Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 200, 642 (2020)
Z. Ali, R. Aman, A. Mahas, G.S. Rao, M. Tehseen, T. Marsic, R. Salunke, A.K. Subudhi, S.M. Hala, S.M. Hamdan, iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Res. 198, 129 (2020)
Authorization, E. U.: LabCorp COVID-19 RT-PCR test EUA Summary (2020). https://www.labcorp.com/coronavirusdisease-covid-19. Accessed 15 May 2020
E.B. Bahadir, M.K. Sezgintürk, Lateral flow assays: Principles, designs and labels. TrAC Trends in Analytical Chemistry 82, 286–306 (2016)
A.N. Baker, S.-J. Richards, C.S. Guy, T.R. Congdon, M. Hasan, A.J. Zwetsloot, A. Gallo, J.Z.R. Lewandowski, P.J. Stansfeld, A. Straube, The SARS-COV-2 spike protein binds sialic acids and enables rapid detection in a lateral flow point of care diagnostic device. ACS Central Science (2020)
K.G. Beavis, S.M. Matushek, A.P.F. Abeleda, C. Bethel, C. Hunt, S. Gillen, A. Moran, V. Tesic, Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. J. Clin. Virol. 104, 468 (2020)
Coronavirus COVID-19 IgM ELISA Assay Kit (2020)
Milenia Biotec, COVID-19 test development with lateral flow & CRISPR “Hybridetect” (2020). https://www.milenia-biotec.com/en/covid-19-rapid-test-development. Accessed 15 May 2020.
J.P. Broughton, X. Deng, G. Yu, C.L. Fasching, V. Servellita, J. Singh, X. Miao, J.A. Streithorst, A. Granados, A. Sotomayor-Gonzalez, CRISPR–Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 1–5 (2020)
R. Bruch, J. Baaske, C. Chatelle, M. Meirich, S. Madlener, W. Weber, C. Dincer, G.A. Urban, CRISPR/Cas13a-powered electrochemical microfluidic biosensor for nucleic acid amplification-free miRNA diagnostics. Adv. Mater. 31, 1905311 (2019)
A.I.L.D. Burog, C.P.R.C. Yacapin, R.R.O. Maglente, A.A. Macalalad-Josue, E.J.B. Uy, Should IgM/IgG rapid test kit be used in the diagnosis of COVID-19? Pacific Center for Evidence Based Healthcare 4, 1–12 (2020)
X. Cai, J. Chen, J. Hu, Q. Long, H. Deng, K. Fan, P. Liao, B. Liu, G. Wu, Y. Chen, A Peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019. J. Infect. Dis. 222(2), 189–193 (2020)
A.D. Cawte, P.J. Unrau, D.S. Rueda, Live cell imaging of single RNA molecules with fluorogenic Mango II arrays. Nat. Commun. 11, 1–11 (2020)
Centers for Disease Control and Prevention: Burden Of Influenza (2020a). https://www.cdc.gov/flu/about/burden/index.html. Accessed 15 May 2020
Centers for Disease Control and Prevention: Coronavirus Disease 2019 COVID-19 (2020b). https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed 15 May 2020
J.F.-W. Chan, C.C.-Y. Yip, K.K.-W. To, T.H.-C. Tang, S.C.-Y. Wong, K.-H. Leung, A.Y.-F. Fung, A.C.-K. Ng, Z. Zou, H.-W. Tsoi, Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J. Clin. Microbiol. 58 (2020a)
J.F.-W. Chan, S. Yuan, K.-H. Kok, K.K.-W. To, H. Chu, J. Yang, F. **ng, J. Liu, C.C.-Y. Yip, R.W.-S. Poon, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 395, 514–523 (2020b)
S. Chekani-Azar, E. Gharib Mombeni, M. Birhan, M. Yousefi, CRISPR/Cas9 gene editing technology and its application to the coronavirus disease (COVID-19), a review. J. Life Sci. Biomed. 10, 01–09 (2020)
A. Chen, S. Yang, Replacing antibodies with aptamers in lateral flow immunoassay. Biosens. Bioelectron. 71, 230–242 (2015)
Z. Chen, Z. Zhang, X. Zhai, Y. Li, L. Lin, H. Zhao, L. Bian, P. Li, L. Yu, Y. Wu, Rapid and sensitive detection of anti-SARS-CoV-2 IgG, Using lanthanide-doped nanoparticles-based lateral flow immunoassay. Anal. Chem. 92, 7226–7231 (2020)
C.D. Chin, T. Laksanasopin, Y.K. Cheung, D. Steinmiller, V. Linder, H. Parsa, J. Wang, H. Moore, R. Rouse, G. Umviligihozo, Microfluidics-based diagnostics of infectious diseases in the develo** world. Nat. Med. 17, 1015 (2011)
D.K. Chu, Y. Pan, S.M. Cheng, K.P. Hui, P. Krishnan, Y. Liu, D.Y. NG, C.K. Wan, P. Yang, Q. Wang, Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin. Chem. 66, 549–555 (2020)
V. Corman, I. Eckerle, T. Bleicker, A. Zaki, O. Landt, M. Eschbach-Bludau, S. van Boheemen, R. Gopal, M. Ballhause, T. Bestebroer, Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Eurosurveillance 17 (2012a)
V. Corman, M. Müller, U. Costabel, J. Timm, T. Binger, B. Meyer, P. Kreher, E. Lattwein, M. Eschbach-Bludau, A. Nitsche, Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Eurosurveillance 17 (2012b)
V. Corman, T. Bleicker, S. Brünink, C. Drosten, M. Zambon, Diagnostic detection of 2019-nCoV by real-time RT-PCR (World Health Organization, 2020)
C. Dincer, R. Bruch, A. Kling, P.S. Dittrich, G.A. Urban, Multiplexed point-of-care testing–xPOCT. Trends Biotechnol. 35, 728–742 (2017)
X. Ding, K. Yin, Z. Li, C. Liu, Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. Nat. Commun. 11(1) (2020)
J. Dinnes, J.J. Deeks, A. Adriano, S. Berhane, C. Davenport, S. Dittrich, D. Emperador, Y. Takwoingi, J. Cunningham, S. Beese, Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev. (2020)
Y. Dong, X. Mo, Y. Hu, X. Qi, F. Jiang, Z. Jiang, S. Tong, Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. 145(6), e20200702 (2020)
J. Elflein, (2020). Available: https://www.statista.com/statistics/1028731/covid19-tests-select-countries-worldwide/
M. Enserink, Update: ‘A bit chaotic.’ Christening of new coronavirus and its disease name create confusion [Online] (2020). Available: https://www.sciencemag.org/news/2020/02/bit-chaotic-christening-new-coronavirus-and-its-disease-name-create-confusion.
Epitope Diagnostics, Inc: ELISA For Novel Coronavirus (2019-Ncov, SARS-Cov-2) Causing an outbreak of pneumonia (COVID-19) — Epitope Diagnostics, Inc. http://www.epitopediagnostics.com/covid-19-elisa (2020). Accessed 15 May 2020
Y. Fang, H. Zhang, J. **e, M. Lin, L. Ying, P. Pang, W. Ji, Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 200, 432 (2020)
H. Feng, Y. Liu, M. Lv, J. Zhong, A case report of COVID-19 with false negative RT-PCR test: Necessity of chest CT. Jpn. J. Radiol. 1–2 (2020)
J. Gallagher, Are coronavirus tests flawed. BBC News, https://www.bbccom/news/health-51491763, 13 (2020)
J. Gao, Z. Tian, X. Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends (2020)
E. Gonzalez-Gonzalez, G. Trujillo-De Santiago, I.M. Lara-Mayorga, S.O. Martinez-Chapa, M.M. Alvarez, Portable and accurate diagnostics for COVID-19: Combined use of the miniPCR thermocycler and a well-plate reader for SARS-CoV-2 virus detection. PLOS One 15(8), e0237418 (2020)
Group, A.:Aptamer Group. 2020. Applications of aptamers in detection and therapeutics of SARS-Cov - Aptamer Group (2020). https://www.aptamergroup.co.uk/applications-of-aptamers-in-detection-and-therapeutics-of-sars-cov. Accessed 15 May 2020
R. Hajian, S. Balderston, T. Tran, T. Deboer, J. Etienne, M. Sandhu, N.A. Wauford, J.-Y. Chung, J. Nokes, M. Athaiya, Detection of unamplified target genes via CRISPR–Cas9 immobilized on a graphene field-effect transistor. Nat. Biomed. Eng. 3, 427–437 (2019)
E. Ortiz-Ospina, H. Ritchie, D. Beltekian, E. Mathieu, J. Hasell, B. Macdonald, C. Giattino, M. Roser, (2020). Available: https://ourworldindata.org/coronavirus-testing#the-scale-of-testing-compared-to-the-scale-of-the-outbreak
C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020)
I.A.E. Huids, T. Madani, F. Ntoumi, R. Koch, O. Dar, The continuing 2019-nCoV epidemicthreatof novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 91, 264–266 (2020)
A.J. Jääskeläinen, E. Kekäläinen, H. Kallio-Kokko, L. Mannonen, E. Kortela, O. Vapalahti, S. Kurkela, M. Lappalainen, Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. Eurosurveillance. 25, 2000603 (2020)
K.J. Jang, N.-R. Lee, W.-S. Yeo, Y.-J. Jeong, D.-E. Kim, Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem. Biophys. Res. Commun. 366, 738–744 (2008)
J. Joung, A. Ladha, M. Saito, N.-G. Kim, A.E. Woolley, M. Segel, R.P. Barretto, A. Ranu, R.K. Macrae, G. Faure, Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing. N. Engl. J. Med. (2020)
M.J. Kellner, J.G. Koob, J.S. Gootenberg, O.O. Abudayyeh, F. Zhang, SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat. Protoc. 14, 2986–3012 (2019)
K.N. Konstantinov, R.A. Sitdikov, G.P. Lopez, P. Atanassov, R.L. Rubin, Rapid detection of anti-chromatin autoantibodies in human serum using a portable electrochemical biosensor. Biosens. Bioelectron. 24, 1949–1954 (2009)
H. Lai, C. Wang, C. Weng, T. Liou, G. Lee, An integrated SELEX microfluidic system for rapid screening of influenza virus specific aptamers. Proceedings of the 16th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Okinawa, Japan, 14021404 (2012)
R. Lassaunière, A. Frische, Z.B. Harboe, A.C. Nielsen, A. Fomsgaard, K.A. Krogfelt, C.S. Jørgensen, Evaluation of nine commercial SARS-CoV-2 immunoassays (Medrxiv, 2020)
E.Y. Lee, M.-Y. Ng, P.-L. Khong, COVID-19 pneumonia: what has CT taught us? Lancet Infect. Dis. 20, 384–385 (2020)
Y. Li, S. Li, J. Wang, G. Liu, CRISPR/Cas systems towards next-generation biosensing. Trends Biotechnol. 37, 730–743 (2019)
X. Li, J. Zai, X. Wang, Y. Li, Potential of large “first generation” human-to-human transmission of 2019-nCoV. J. Med. Virol. 92, 448–454 (2020a)
Z. Li, Y. Yi, X. Luo, N. **ong, Y. Liu, S. Li, R. Sun, Y. Wang, B. Hu, W. Chen, Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J. Med. Virol. 92(9), 1518–1524 (2020)
S. Liebich, Potent SELEX aptamer-based therapeutic method for novel SARS-CoV2 virus disease (COVID-19) (2020)
F. Hoffmann-La Roche Ltd, Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care [Online] ( 2020a). Available: https://www.roche.com/media/releases/med-cor-2020-09-01b.htm
F. Hoffmann-La Roche Ltd, Elecsys Anti-SARS-CoV-2 (2020b)
Iceni Diagnostics Ltd, Rapid COVID-19 detection – Iceni Diagnostics offers new approach [Online] (n.d.). Available: https://www.icenidiagnostics.com/news/rapid-covid-19-detection-iceni-diagnostics-offers-new-approach/
H. Lu, Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends 14, 69–71 (2020)
H. Ma, W. Zeng, H. He, D. Zhao, D. Jiang, P. Zhou, L. Cheng, Y. Li, X. Ma, T. **, Serum IgA, IgM, and IgG responses in COVID-19. Cell. Mol. Immunol. 1–3 (2020)
G.C. Mak, P.K. Cheng, S.S. Lau, K.K. Wong, C. Lau, E.T. Lam, R.C. Chan, D.N. Tsang, Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. J. Clin. Virol. 104, 500 (2020)
A.W. Martinez, S.T. Phillips, E. Carrilho, S.W. Thomas III, H. Sindi, G.M. Whitesides, Simple telemedicine for develo** regions: camera phones and paper-based microfluidic devices for real-time, off-site diagnosis. Anal. Chem. 80, 3699–3707 (2008)
S. Misra, Biotech startup with MIT Tata Center roots produces 15-min tests for Covid-19 [Online] (2020). Available: http://energy.mit.edu/news/mit-tata-center-startup-e25bio-produces-15-minute-tests-for-covid-19/
P. Moitra, M. Alafeef, K. Dighe, M. Frieman, D. Pan, Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano. 14(6), 7617–7627 (2020)
E. Morales-Narváez, C. Dincer, The impact of biosensing in a pandemic outbreak: COVID-19. Biosens. Bioelectron. 112, 274 (2020)
M.A. Mujawar, H. Gohel, S.K. Bhardwaj, S. Srinivasan, N. Hickman, A. Kaushik, Aspects of nano-enabling biosensing systems for intelligent healthcare; towards COVID-19 management. Mater. Today Chem. 100, 306 (2020)
F.B. Myers, L.P. Lee, Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab Chip 8, 2015–2031 (2008)
S. Nanotech, Sona Nanotech provides Covid-19 antigen test progress update [Online] (2020). Available: https://sonanano.com/sona-nanotech-provides-covid-19-antigen-test-progress-update/
B.W. Neuman, G. Kiss, A.H. Kunding, D. Bhella, M.F. Baksh, S. Connelly, B. Droese, J.P. Klaus, S. Makino, S.G. Sawicki, A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol. 174, 11–22 (2011)
Genetic Engineering and Biotechnology News: COVID-19 test kits being developed using RNA imaging (2020). https://www.genengnews.com/news/covid-19-test-kits-being-developed-using-rna-imaging. Accessed 15 May 2020.
T. Nicol, C. Lefeuvre, O. Serri, A. Pivert, F. Joubaud, V. Dubée, A. Kouatchet, A. Ducancelle, F. Lunel-Fabiani, H. Le Guillou-Guillemette, Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). J. Clin. Virol. 129, 104511 (2020)
H. Nishiura, H. Oshitani, T. Kobayashi, T. Saito, T. Sunagawa, T. Matsui, T. Wakita, M. Covid, M. Suzuki, Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19) (MedRxiv, 2020)
E. Nunez-Bajo, M. Kasimatis, Y. Cotur, T. Asfour, A. Collins, U. Tanriverdi, M. Grell, M. Kaisti, G. Senesi, K. Stevenson, Ultra-low-cost integrated silicon-based transducer for on-site, genetic detection of pathogens (bioRxiv, 2020)
G. Onder, G. Rezza, S. Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA (2020)
World Health Organization (WHO), Home (2020). https://www.who.int. Accessed 15 May 2020.
OraSure Technologies, I.: Orasure Technologies, Inc. Announces 2020 Second quarter financial results and update On COVID-19 testing programs. GlobeNewswire News Room (2020). https://www.globenewswire.com/news-release/2020/08/05/2073582/0/en/OraSure-Technologies-Inc-Announces-2020-Second-Quarter-Financial-Resultsand-Update-on-COVID-19-Testing-Programs.html. Accessed 15 May 2020.
A. Pickar-Oliver, C.A. Gersbach, The next generation of CRISPR–Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490–507 (2019)
R. Racine, G.M. Winslow, IgM in microbial infections: taken for granted? Immunol. Lett. 125, 79–85 (2009)
J.N. Rauch, E. Valois, S.C. Solley, F. Braig, R.S. Lach, N.J. Baxter, K.S. Kosik, C. Arias, D. Acosta-Alvear, M.Z. Wilson, A scalable, easy-to-deploy, protocol for Cas13-based detection of SARS-CoV-2 genetic material (bioRxiv, 2020)
D. Schoeman, B.C. Fielding, Coronavirus envelope protein: current knowledge. Virol. J. 16, 69 (2019)
G. Seo, G. Lee, M.J. Kim, S.-H. Baek, M. Choi, K.B. Ku, C.-S. Lee, S. Jun, D. Park, H.G. Kim, Rapid detection of Covid-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 14(4), 5135–5142 (2020)
B. Shan, Y.Y. Broza, W. Li, Y. Wang, S. Wu, Z. Liu, J. Wang, S. Gui, L. Wang, Z. Zhang, Multiplexed nanomaterial-based sensor array for detection of COVID-19 in exhaled breath. ACS Nano 14, 12125–12,132 (2020)
K.K.-W. To, O.T.-Y. Tsang, W.-S. Leung, A.R. Tam, T.-C. Wu, D.C. Lung, C.C.-Y. Yip, J.-P. Cai, J.M.-C. Chan, T.S.-H. Chik, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20(5), 565–574 (2020)
J. Tu, R.M. Torrente-Rodríguez, M. Wang, W. Gao, The era of digital health: A review of portable and wearable affinity biosensors. Adv. Funct. Mater. 1, 906713 (2019)
B. Udugama, P. Kadhiresan, H.N. Kozlowski, A. Malekjahani, M. Osborne, V.Y. Li, H. Chen, S. Mubareka, J.B. Gubbay, W.C. Chan, Diagnosing COVID-19: the disease and tools for detection. ACS Nano 14, 3822–3835 (2020)
Z. Wan, X. Zhang, X. Yan, IFA in testing specific antibody of SARS coronavirus. South China J Prev. Med. 29, 36–37 (2003)
P. Wang, Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections. J. Virol. Methods 283, 113919 (2020)
C. Wang, W. Li, D. Drabek, N.M. Okba, R. Van Haperen, A.D. Osterhaus, F.J. Van Kuppeveld, B.L. Haagmans, F. Grosveld, B.-J. Bosch, A human monoclonal 1 antibody blocking SARS-CoV-2 infection (Biorxiv, 2020a)
M. Wang, A. Fu, B. Hu, Y. Tong, R. Liu, J. Gu, J. Liu, W. Jiang, G. Shen, W. Zhao, Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses (medRxiv, 2020b)
S.K. Wee, S.P. Sivalingam, E.P.H. Yap, Rapid Direct Nucleic Acid Amplification Test without RNA Extraction for SARS-CoV-2 using a Portable PCR Thermocycler (bioRxiv, 2020)
S.R. Weiss, J.L. Leibowitz, Coronavirus pathogenesis. Adv. Virus Res. (Elsevier, 2011)
C. Weiss, M. Carriere, L. Fusco, I. Capua, J.A. Regla-Nava, M. Pasquali, J.A. Scott, F. Vitale, M.A. Unal, C. Mattevi, Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano. 14(6), 6383–6406 (2020)
T. Wen, C. Huang, F.-J. Shi, X.-Y. Zeng, T. Lu, S.-N. Ding, Y.-J. Jiao, Development of a lateral flow immunoassay strip for rapid detection of IgG antibody against SARS-CoV-2 virus. Analyst 145, 5345–5352 (2020)
D. Wrapp, N. Wang, K.S. Corbett, J.A. Goldsmith, C.-L. Hsieh, O. Abiona, B.S. Graham, J.S. Mclellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020)
T.T. Yao, J.D. Qian, W.Y. Zhu, Y. Wang, G.Q. Wang, A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option. J. Med. Virol. 92(6), 556–563 (2020)
Y. Yuan, D. Cao, Y. Zhang, J. Ma, J. Qi, Q. Wang, G. Lu, Y. Wu, J. Yan, Y. Shi, Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8, 15092 (2017)
D. Zhang, Q. Liu, Biosensors and bioelectronics on smartphone for portable biochemical detection. Biosens. Bioelectron. 75, 273–284 (2016)
Z. Zhao, H. Cui, W. Song, X. Ru, W. Zhou, X. Yu, A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2 (bioRxiv, 2020)
P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020)
N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382(8), 727-733 (2020)
L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang, Z. Hong, J. Yu, M. Kang, Y. Song, J. **a, SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177–1179 (2020)
Acknowledgements
We gratefully acknowledge Gujarat State Biotechnology Mission (GSBTM Project ID: AJJV48) and SHODH: ScHeme of Develo** High Quality Research Scholarship (Ref No: 201901440009) for financial support.
Author information
Authors and Affiliations
Contributions
All the authors have contributed equally.
Corresponding author
Ethics declarations
Conflicts of interest/competing interests
Authors declare no conflict of interest.
Ethics approval
Not applicable.
Consent for publication
Not applicable.
Code availability
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Verma, N., Patel, D. & Pandya, A. Emerging diagnostic tools for detection of COVID-19 and perspective. Biomed Microdevices 22, 83 (2020). https://doi.org/10.1007/s10544-020-00534-z
Accepted:
Published:
DOI: https://doi.org/10.1007/s10544-020-00534-z